Literature DB >> 7843756

Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension.

A Soro1, M C Ingram, G Tonolo, N Glorioso, R Fraser.   

Abstract

We compared corticosteroid metabolite excretion rates and patterns in a group of 68 subjects with untreated essential hypertension and a matched group of 48 normotensive control subjects. The ratio of tetrahydrocortisol plus allotetrahydrocortisol to tetrahydrocortisone and the ratio of allotetrahydrocortisol to tetrahydrocortisol were significantly higher in the hypertensive group. This is qualitatively similar to the situation found in patients with the syndrome of apparent mineralocorticoid excess or subjects treated with licorice or carbenoxolone where hypertension is known to arise from deficiencies of 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activities. The equivalent ratios for corticosterone metabolites were not different between groups, but total corticosterone metabolite excretion was higher in the hypertensive group. Plasma cortisol levels were lower in hypertensive than in control subjects, but corticosterone levels were higher. This evidence supports a previous suggestion that the activities of these two enzymes may be reduced in essential hypertension, but the contribution of these changes to hypertension is not known.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7843756     DOI: 10.1161/01.hyp.25.1.67

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  14 in total

Review 1.  Aldosterone-related genetic effects in hypertension.

Authors:  D G Warnock
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

2.  Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor.

Authors:  J A Whitworth; J J Kelly
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

3.  Further studies on the mechanism of the mineralocorticoid action of licorice in humans.

Authors:  D Armanini; S Lewicka; C Pratesi; M Scali; M C Zennaro; S Zovato; C Gottardo; M Simoncini; A Spigariol; V Zampollo
Journal:  J Endocrinol Invest       Date:  1996-10       Impact factor: 4.256

Review 4.  The epithelial sodium channel in hypertension.

Authors:  D G Warnock
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

5.  Role of ketoconazole treatment in urinary-free cortisol-to-cortisone and tetrahydrocortisol-to-tetrahydrocortisone ratios in nonectopic Cushing's syndrome.

Authors:  Pablo Stiefel; José S García-Morillo; Luis Jimenez; Encarnación Pamies; María Luisa Miranda; Joaquín Carneado; José Villar; Alfonso Leal-Cerro
Journal:  Endocrine       Date:  2002-08       Impact factor: 3.633

6.  Urinary cortisol to cortisone metabolites in hypertensive obese children.

Authors:  G Y Csábi; S Juricskay; D Molnár
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

7.  11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension.

Authors:  Carmen Campino; Cristian A Carvajal; Javiera Cornejo; Betty San Martín; Oliviero Olivieri; Giancesare Guidi; Giovanni Faccini; Francesco Pasini; Javiera Sateler; Rene Baudrand; Lorena Mosso; Gareth I Owen; Alexis M Kalergis; Oslando Padilla; Carlos E Fardella
Journal:  Endocrine       Date:  2009-10-31       Impact factor: 3.633

8.  Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.

Authors:  A Li; R Tedde; Z S Krozowski; A Pala; K X Li; C H Shackleton; F Mantero; M Palermo; P M Stewart
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

9.  Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2.

Authors:  R W Brown; K E Chapman; Y Kotelevtsev; J L Yau; R S Lindsay; L Brett; C Leckie; P Murad; V Lyons; J J Mullins; C R Edwards; J R Seckl
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

10.  11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension.

Authors:  Lama Ghazi; Tanja Dudenbostel; Maria El Hachem; Mohammed Siddiqui; Chee Paul Lin; Suzanne Oparil; David A Calhoun
Journal:  Am J Hypertens       Date:  2017-05-01       Impact factor: 2.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.